Barriers to hepatitis C treatment

被引:141
|
作者
McGowan, Christopher E. [1 ]
Fried, Michael W. [1 ]
机构
[1] Univ N Carolina, Sch Med, UNC Liver Ctr, Div Gastroenterol & Hepatol, Chapel Hill, NC 27599 USA
基金
美国国家卫生研究院;
关键词
delivery of health care; barriers to care; health services accessibility; hepatitis C; therapy; INJECTION-DRUG USERS; VIRUS-INFECTION; ANTIVIRAL THERAPY; PLUS RIBAVIRIN; CARE; MANAGEMENT; KNOWLEDGE; VETERANS; OUTCOMES; RATES;
D O I
10.1111/j.1478-3231.2011.02706.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Despite the availability of highly effective therapy for hepatitis C virus (HCV) infection, few patients receive treatment. Barriers arising at multiple levels, from diagnosis to specialist referral, may impede the delivery of hepatitis C care. At the patient level, lack of awareness, fear of side effects, poor adherence and comorbid conditions may prevent treatment. For providers, limited knowledge, lack of availability and communication difficulties may be problematic. At the government and payer level, a lack of promotion, surveillance and funding may interfere. Each of these barriers needs to be addressed if wider implementation of antiviral therapy is to be achieved.
引用
收藏
页码:151 / 156
页数:6
相关论文
共 50 条
  • [31] Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection
    Clark, Brian T.
    Garcia-Tsao, Guadalupe
    Fraenkel, Liana
    PATIENT PREFERENCE AND ADHERENCE, 2012, 6 : 285 - 295
  • [32] Knowledge About Hepatitis-C Among Methadone Maintenance Treatment Patients in Israel
    Cohen-Moreno, Rinat
    Schiff, Miriam
    Levitt, Shabtay
    Bar-Hamburger, Rachel
    Strauss, Shiela
    Neumark, Yehuda
    SUBSTANCE USE & MISUSE, 2010, 45 (1-2) : 58 - 76
  • [33] Primary Care and Hepatology Provider-Perceived Barriers to and Facilitators of Hepatitis C Treatment Candidacy and Adherence
    Rogal, Shari S.
    McCarthy, Rory
    Reid, Andrea
    Rodriguez, Keri L.
    Calgaro, Linda
    Patel, Krupa
    Daley, Molly
    Jonassaint, Naudia L.
    Zickmund, Susan L.
    DIGESTIVE DISEASES AND SCIENCES, 2017, 62 (08) : 1933 - 1943
  • [34] Experiences with interferon-free hepatitis C therapies: addressing barriers to adherence and optimizing treatment outcomes
    Skolnik, Avy A.
    Noska, Amanda
    Yakovchenko, Vera
    Tsai, Jack
    Jones, Natalie
    Gifford, Allen L.
    McInnes, D. Keith
    BMC HEALTH SERVICES RESEARCH, 2019, 19 (1)
  • [35] Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C
    Cuenca-Lopez, Francisca
    Rivero, Antonio
    Rivero-Juarez, Antonio
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (01) : 105 - 112
  • [36] Identifying Barriers to the Treatment of Chronic Hepatitis C Infection
    Al-Khazraji, Ahmed
    Patel, Ishan
    Saleh, Mohammed
    Ashraf, Amar
    Lieber, Joseph
    Malik, Raza
    DIGESTIVE DISEASES, 2020, 38 (01) : 46 - 52
  • [37] Hepatitis C and Social Work
    Mack, Heather
    Paylor, Ian
    BRITISH JOURNAL OF SOCIAL WORK, 2016, 46 (04): : 1115 - 1130
  • [38] Barriers to treatment of chronic hepatitis C with direct acting antivirals in an urban clinic
    Malespin, Miguel
    Harris, Ciel
    Kanar, Ozdemir
    Jackman, Kelly
    Smotherman, Carmen
    Johnston, Abbey
    Ferm, Julie
    de Melo, Silvio W., Jr.
    Scolapio, James S.
    Nelson, David R.
    Cotler, Scott J.
    ANNALS OF HEPATOLOGY, 2019, 18 (02) : 304 - 309
  • [39] SIMPLIFIED TREATMENT OF HEPATITIS C: ANOTHER STRATEGY TO OVERCOME THE BARRIERS TO ITS ELIMINATION
    Ridruejo, Ezequiel
    Mendizabal, Manuel
    Silva, Marcelo O.
    MEDICINA-BUENOS AIRES, 2021, 81 (02) : 252 - 256
  • [40] Subspecialty physicians' perspectives on barriers and facilitators of hepatitis C treatment: a qualitative study
    Bredenberg, Erin
    Callister, Catherine
    Dafoe, Ashley
    Holliman, Brooke Dorsey
    Rowan, Sarah E.
    Calcaterra, Susan L.
    HARM REDUCTION JOURNAL, 2024, 21 (01)